According to The Insight Partners' research, the North America Embolization Plugs Market was valued at US$ 127.4 Million in 2024 and is expected to reach US$ 230.2 Million by 2031, registering a CAGR of 8.9% from 2025 to 2031.
Adoption of low-profile micro-delivery systems and the rise of bioresorbable and biodegradable plugs are among the critical factors attributed to drive the North America embolization plugs market.
In the rapidly evolving embolization plugs market, low-profile micro-delivery systems represent a transformative trend, enabling precise, minimally invasive occlusion of small-caliber vessels. These systems, compatible with microcatheters (0.021- to 0.027-inch inner diameter), facilitate super-selective embolization in challenging anatomies, reducing procedural time, radiation exposure, and complication risks compared to traditional larger-profile devices. This shift aligns with the broader demand for endovascular therapies treating vascular malformations, tumors, and hemorrhages, where distal access is paramount.
A prime example is Medtronic's MVP Micro Vascular Plug system. The MVP-3 and MVP-5 models deploy through flexible microcatheters, achieving immediate occlusion in vessels as small as 3-5 mm. In a retrospective study of 104 patients across emergent (e.g., trauma-induced bleeding) and elective (e.g., tumor devascularization) scenarios, the MVP system yielded a 90.9% technical success rate, with no device-related major complications, as reported in CVIR Endovascular (2021). This underscores its reliability in high-flow or tortuous vessels, where redeployment was feasible in 30% of cases without migration, per a Cardiovascular and Interventional Radiological Society of Europe (CIRSE) analysis.
Terumo Medical Corporation's AZUR Vascular Plug is the first microcatheter-compatible device that occludes arteries up to 8 mm. It expands Terumo's portfolio for peripheral embolization, enhancing precision in oncology and neurology applications. Adoption is accelerating, propelled by rising peripheral artery disease prevalence and a significant growth for embolization coils through 2034, as non-coil plugs such as this gain traction for their superior control. In a 33-patient cohort using MVP plugs for peripheral applications, technical success reached 90.9%, with 66.7% combining plugs and other agents for hybrid efficacy, as detailed in Biomedicines (2023). Thus, low-profile systems could redefine embolization, prioritizing patient safety and procedural efficiency in an aging population prone to vascular disorders during the forecast period.
On the contrary, high development and device costs hinder widespread adoption hampers the growth of the North America embolization plugs market.
North America Embolization Plugs Market Segmentation Analysis:
- By Application, the North America Embolization Plugs Market is segmented into Neurology, Peripheral Vascular Disease, Oncology, Urology, and Others. The Neurology segment is projected to expand at a CAGR of 9.5% during 2025 - 2031.
- By End User, the North America Embolization Plugs Market is segmented into hospitals, Ambulatory Centers, and Others. The Hospital segment is projected to expand at a CAGR of 9.4% during 2025 - 2031.
By country, the North America Embolization Plugs Market is categorized into the United States, Canada and Mexico. The United States is projected to expand at a CAGR of 9.1% during 2025 - 2031.
Key players operating in the Embolization Plugs Market are Merit Medical Systems Inc, Abbott Laboratories, Terumo Corp, Medtronic Plc, Shape Memory Medical, Lifetech Scientific Corp, INVAMED, ArtVentive Medical Group, among others.
In October 2025, Shape Memory Medical Inc. announced that it had received approvals from both Singapore's Health Science Authority (HSA) and Malaysia's Medical Device Authority (MDA) to market the IMPEDE Embolization Plug, the IMPEDE-FX Embolization Plug, and the IMPEDE-FX RapidFill System. Getz Healthcare Pty Ltd, which is a member of the privately held Getz Group of Companies, has been instrumental in driving the approval process and serves as Shape Memory Medical's distribution partner for its peripheral embolization portfolio.
In October 2024, Merit Medical Systems, Inc. announced the United States launch of its Siege vascular plug, which received FDA 510(k) clearance earlier this year. According to the company, the nitinol, self-expanding Siege vascular plug for peripheral artery embolization is designed to be highly deliverable and recapturable to enable precise placement while achieving vessel occlusion within 1.3 minutes.
Contact Us
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com